HIF prolyl-hydroxylase inhibitors are members of a class of new drugs that act on the hypoxia-inducible factor (HIF) pathway.
As of 2008 they are being investigated for treatment of anemia, chronic kidney disease, cancer, and for their effects on heart tissue and others.
Research conducted in mice suggests that they may increase hippocampal memory by increasing erythropoietin expression.
They act by inhibiting HIF prolyl-hydroxylase enzymes.
References
HIF prolyl-hydroxylase inhibitor Wikipedia(Text) CC BY-SA